Detection of larvae of Toxocara canis in milk: an experimental study in rabbits.

Toxocariasis, caused most commonly by Toxocara canis, is an important cosmopolitan zoonosis. Paratenic hosts have been employed to provide knowledge regard to the transmission of toxocariasis. Transmammary transmission in murine experimentally infected was observed based on the recovery of larvae from the tissue. The aim of this study was to evaluate the possibility of transmammary transmission of Toxocara canis in rabbits by detecting larvae directly in milk. Seventeen sexually mature virgin white New Zealand female rabbits were divided into two groups. Twelve animals were orally inoculated with 1,000 T. canis embryonated eggs (infected group), and five animals remained uninfected (control group). One month following the infection, the females were mated. Manual collection of 500 ?L of milk from each rabbit was performed on days +7, +14 and +21 of lactation for three consecutive lactations. The recovery of larvae was determined via a centrifuge-sedimentation technique using ether and formalin solutions. ELISA test was run to confirm the production of anti-T. canis antibodies (IgG) by infected rabbits. The presence of larvae was observed in milk samples from 5 (41.7%) of the 12 infected rabbits. The total number of recovered larvae was 20, ranging from 1 to 4 larvae per lactation/rabbit. Larvae were recovered exclusively on days 7 and 14 of lactation. Recovery was verified in different lactations. No significant difference was observed with respect to the number of larvae either in the same lactation period or in different lactation periods. Anti-T. canis antibodies were detected in all infected rabbits. In conclusion, the presence of larvae in rabbit milk samples suggests the possibility of galactogenic transmission of T. canis in paratenic hosts. Moreover, the technique employed in this study allows for the recovery of larvae directly from milk.

Verhaltensphysiologische Experimente zur Erkennung und Unterscheidung menschlicher Gesichter beim Haushund (Canis familiaris)

In der vorliegenden Arbeit wurde die Fähigkeit von Hunden zur Erkennung und Unterscheidung menschlicher Gesichter untersucht. Zu diesem Zweck wurden verschiedene Verhaltensexperimente mit fünf Hunden durchgeführt. Zunächst wurden die Hunde darauf dressiert, ein einlaminiertes DIN A4 Blatt mit einem Gesicht im Zentrum in der dafür vorgesehenen Apparatur mit der Schnauze zu berühren. Bei der Dressur wurden immer zwei Folien präsentiert, wobei nur eine Wahl, nämlich die des Dressurgesichts, durch Futtergabe belohnt wurde. Nach Abschluss der Dressurphase wurden die Hunde in Generalisationstests mit neuen Gesichtern konfrontiert, die für uns Menschen wenig bis keine direkte Ähnlichkeit mit dem Dressurgesicht aufwiesen. Um herauszufinden ob Hunde sich an der Größe orientieren, wurden einige der zuvor getesteten Gesichter um die Hälfte und mehr verkleinert. All diese Veränderungen beeinträchtigten die Fähigkeit der Hunde nicht, das Dressurgesicht bevorzugt zu wählen. Diese Ergebnisse veranlassten die Versuchsleiterin zu testen, ob Hunde sich an verschiedenen Bereichen im menschlichen Gesicht orientieren oder das Gesicht als Ganzes wahrnehmen. Zur Beurteilung wurden den Hunden abgeänderte Gesichter zum Einen ohne Haare und Ohren und zum Anderen nur Haare und Ohren ohne das Gesicht (homogen graue Fläche) präsentiert. Hier hatten die Hunde deutliche Schwierigkeiten, wenn die äußeren Konturen nicht mehr vorhanden waren. Bei diesen Versuchen blieben die Wahlen der Hunde nahe dem Zufallsniveau von 50%. Das Fehlen des Gesichts als solches erwies sich als unproblematisch, da allen Hunden die äußeren Konturen, in diesem Fall Haare und Ohren ausreichten, um das Dressurgesicht mit einer Wahlhäufigkeit signifikant über 70% wiederzuerkennen. Abschließend wurde untersucht, ob sich die Hunde durch das Zusammensetzen von zwei bzw. drei unterschiedlichen Gesichtern in ihrem Wahlverhalten beeinflussen lassen. Dazu wurden zwei unterschiedlichen Haarpartien verschiedene Gesichter zugeordnet. Ähnelten sich die äußeren Konturen fiel es den Hunden in dieser Versuchsreihe schwer die Dressurhaare wieder zu erkennen. Unterschieden sich die äußeren Konturen für unser menschliches Auge deutlich, so wählten alle Hunde die Haare und Ohren des Dressurgesichts mit einer Wahlhäufigkeit signifikant über dem Schwellenwert von 70%. Somit ist zu vermuten, dass sich im Laufe der Domestikation beim Hund keine Hirnregion ausgebildet hat, die speziell für die Gesichtserkennung von Menschen verantwortlich ist. Aus den Ergebnissen dieser Arbeit zur Gesichtserkennung beim Hund wird deutlich, dass es dem Hund möglich ist, Gesichter voneinander zu unterscheiden. Allerdings orientiert sich der Hund nicht an bestimmten Gesichtsregionen, sondern nutzt die äußeren Konturen als Wiedererkennungsmerkmal. Aus diesem Grund finden sich häufig Unsicherheiten bei Hunden, wenn ihnen bekannte Menschen plötzlich mit Hut oder Mütze begegnen und eine Erkennung über den Geruchssinn und die Stimme noch nicht stattgefunden hat. Bei der Beurteilung der Ergebnisse muss beachtet werden, dass den Hunden das menschliche Gesicht in Form von Bildern präsentiert wurde und somit keine Beeinflussung durch Bewegung im Gesicht gegeben war. Da das Bewegungssehen beim Hund sehr gut ausgebildet ist, achtet er im Alltag des Menschen sehr wahrscheinlich außerordentlich gut auf Augenbewegungen und Gesichtsmuskelbewegungen, um mit dem Sozialpartner Mensch zu kommunizieren. Weiterhin wäre es interessant herauszufinden, ob die Orientierung an den äußeren Konturen eine Folge der Domestikation und somit eine Adaptation an den Menschen und sein Ökosystem ist, oder ob Wölfe auch dazu in der Lage wären.

Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan

Systemic lupus erythematosus is a chronic autoimmune disorder that predominantly affects women of childbearing age. Lupus-associated glomerulonephritis is a major cause of mortality in these patients. Current treatment protocols for systemic lupus erythematosus include cyclophosphamide, prednisolone, azathioprine, and mycophenolate mofetil. However, in mice none of these agents alone or in combination were shown to reverse established proteinuria. Using New Zealand Black x New Zealand White F1 mice, we report that administration of the topoisomerase I inhibitor irinotecan from week 13 completely prevented the onset of proteinuria and prolonged survival up to at least 90 wk without detectable side effects. Furthermore, application of irinotecan to mice with established lupus nephritis, as indicated by grade 3+ (> or =300 mg/dl) and grade 4+ (> or =2000 mg/dl) proteinuria and, according to a median age of 35 wk, resulted in remission rates of 75% and 55%, respectively. Survival was significantly prolonged with 73 wk (grade 3+ and 4+ combined) versus 40 wk for control animals. Although total IgG and anti-dsDNA Abs in the serum and mesangial IgG deposits in the kidneys were not reduced in irinotecan-treated mice, subendothelial immune deposits were considerably diminished, suggesting a prevention of glomerular basement membrane disruption. This effect was accompanied by increased rates of ssDNA breaks and inhibition of renal cell apoptosis being different to what is known about irinotecan in anticancer therapy. In conclusion, our data provide evidence that irinotecan might represent an entirely new strategy for the treatment of systemic lupus erythematosus.

Screening for lupus anticoagulant: improving the performance of the lupus-sensitive PTT-LA

Introduction: The aim of the present work was to verify whether calculating a ratio between clotting times obtained with the sensitive PTT-LA and a less sensitive activated partial thromboplastin time (aPTT)-reagent may represent a valuable aPTT-based screening strategy for lupus anticoagulants (LA). Methods: For the pilot study, plasma samples from normal subjects (n = 15) and from patients with LA (n = 10), therapeutic anticoagulation with vitamin K-antagonists (VKA) (n = 15) or unfractionated heparin (n = 15), coagulation factors deficiency (n = 16), and inhibitory antibodies against factor VIII or IX (n = 11) were studied. For the evaluation study, 1553 consecutive plasma samples from nonanticoagulated patients investigated for LA between January 2005 and December 2007 at our institution were studied. Following screening strategies were employed: Pathromtin-SL (aPTT-SL), PTT-LA (aPTT-LA), ratio aPTT-LA/aPTT-SL (aPTT-ratio), and Russell's viper venom (RVV) based LA-Check. LA positive samples were identified by mixing studies and diluted RVV confirmation test (LA-Check/LA-Sure). Results: Pilot study: All screening strategies had a 100% sensitivity, and the aPTT-ratio reached the highest specificity (82%; 95%CI: 74-90%). Within the evaluation study, following sensitivities for LA screening were observed: aPTT-SL 59.0% (95%CI: 57-61%), aPTT-LA 82.1% (95%CI: 80-84%), aPTT-ratio 92.3% (95%CI: 91-94), and LA-Check 83.3% (95%CI: 82-85%). Conclusion: Calculating a ratio between the LA-sensitive PTT-LA and the less sensitive Pathromtin-SL improves the performance of the PTT-LA itself and represents a simple and sensitive aPTT-based integrated strategy for LA screening.

Linear sclerodermic lupus erythematosus, a distinct variant of linear morphea and chronic cutaneous lupus erythematous

Overlap syndromes represent disorders that combine diagnostic criteria of two or more different connective tissue diseases.

Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report

Systemic lupus erythematosus (SLE) can be a severe and potentially life-threatening disease that often represents a therapeutic challenge because of its heterogeneous organ manifestations. Only glucocorticoids, chloroquine and hydroxychloroquine, azathioprine, cyclophosphamide and very recently belimumab have been approved for SLE therapy in Germany, Austria and Switzerland. Dependence on glucocorticoids and resistance to the approved therapeutic agents, as well as substantial toxicity, are frequent. Therefore, treatment considerations will include 'off-label' use of medication approved for other indications. In this consensus approach, an effort has been undertaken to delineate the limits of the current evidence on therapeutic options for SLE organ disease, and to agree on common practice. This has been based on the best available evidence obtained by a rigorous literature review and the authors' own experience with available drugs derived under very similar health care conditions. Preparation of this consensus document included an initial meeting to agree upon the core agenda, a systematic literature review with subsequent formulation of a consensus and determination of the evidence level followed by collecting the level of agreement from the panel members. In addition to overarching principles, the panel have focused on the treatment of major SLE organ manifestations (lupus nephritis, arthritis, lung disease, neuropsychiatric and haematological manifestations, antiphospholipid syndrome and serositis). This consensus report is intended to support clinicians involved in the care of patients with difficult courses of SLE not responding to standard therapies by providing up-to-date information on the best available evidence.

Serum cytokine profile in patients with active lupus nephritis

Determination of disease activity of lupus nephritis remains challenging. Since cytokines play a role as inflammatory mediators extending renal injury, measuring serum cytokine levels might help in the clinical assessment of patients with lupus nephritis. Therefore, the aim of this study was to determine the diagnostic value of a panel of serum cytokines in patients with active lupus nephritis.

Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network

Despite new treatment options, some patients with systemic lupus erythematosus (SLE) need to be treated with the cytotoxic agent cyclophosphamide (CYC). Unlike malignant disease, there are no recommendations for ovarian protection in SLE. The clinical experience of the FertiPROTEKT network as well as recommendations after literature review will be presented in this paper.

Facets of lupus erythematosus: panniculitis responding to thalidomide

Lupus erythematosus profundus or lupus panniculitis is a rare clinical variant of lupus erythematosus, which involves the deep dermis and subcutaneous fat. Diagnosis may be difficult in cases with isolated involvement. Further manifestations of lupus erythematosus may thus be essential for diagnosis, which depends on the clinical picture, histopathology and a positive lesional lupus band test. We report a severe, mutilating case of lupus panniculitis, which responded well to thalidomide.